Ann: SYNThesis BioVentures MoU for cellular immunotherapies, page-37

Yes you are correct

1AD less than $15m MC and will be going into Phase 2 trials.

NYR at ~$26m MC and still at pre-clinical trials.

I really don't get why any holder is selling at 2.8c. It makes zero sense.

As stated, Tim is working with some large Pharma's on a deal. This would put 1AD in a great position, when announced.

It could drop at anytime and those options expire next month, so he would want the share price to be significantly higher. He said near term so i would think in the next month or so!!

Lets see if he pulls a surprise out of the bag, like yesterday